(Q34746490)

4 August 2017

1 reference

title

Exploiting viral properties for the rational design of modern vaccines (English)

1 reference

4 August 2017

1 reference

2

Martin F Bachmann

1 reference

4 August 2017

Gunther Spohn

1

1 reference

4 August 2017

publication date

1 February 2008

1 reference

Expert Review of Vaccines

4 August 2017

published in

1 reference

4 August 2017

volume

7

1 reference

4 August 2017

issue

1

1 reference

4 August 2017

page(s)

43-54

1 reference

Vaccines: past, present and future

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.1.43

Can successful vaccines teach us how to induce efficient protective immune responses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.1.43

Targeting to macrophages: role of physicochemical properties of particulate carriers--liposomes and microspheres--on the phagocytosis by macrophages.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.1.43

Pattern recognition receptors: doubling up for the innate immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.1.43

The role of complement and complement receptors in induction and regulation of immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.1.43

Cellular mechanisms governing cross-presentation of exogenous antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.1.43

The complex route to MHC class I-peptide complexes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.1.43

Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.1.43

Loading of MHC class I and II presentation pathways by exogenous antigens: a quantitative in vivo comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.1.43

Recognition and signaling by toll-like receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.1.43

Cooperation of Toll-like receptor signals in innate immune defence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.1.43

Toll-like receptors and RNA helicases: two parallel ways to trigger antiviral responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.1.43

5'-Triphosphate RNA is the ligand for RIG-I

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.1.43

RIG-I-mediated antiviral responses to single-stranded RNA bearing 5'-phosphates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.1.43

DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.1.43

Innate immune recognition of viral infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.1.43

The influence of virus structure on antibody responses and virus serotype formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.1.43

Neutralizing antiviral B cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.1.43

T helper cell-independent neutralizing B cell response against vesicular stomatitis virus: role of antigen patterns in B cell induction?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.1.43

Determinants of autoantibody induction by conjugated papillomavirus virus-like particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.1.43

Specific cellular stimulation in the primary immune response: experimental test of a quantized model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.1.43

Effector and memory T-cell differentiation: implications for vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.1.43

Memory CD8 T-cell differentiation during viral infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.1.43

Early programming of T cell populations responding to bacterial infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.1.43

The duration of antigenic stimulation determines the fate of naive and effector T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.1.43

Long-lived memory CD8+ T cells are programmed by prolonged antigen exposure and low levels of cellular activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.1.43

Immunogenicity and protectivity of a new liposomal hepatitis A vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.1.43

ISCOM-based vaccines: the second decade.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.1.43

Immune stimulating complexes as mucosal vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.1.43

Vaccines that facilitate antigen entry into dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.1.43

Molecularly engineered poly(ortho ester) microspheres for enhanced delivery of DNA vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.1.43

Oral gene delivery with chitosan--DNA nanoparticles generates immunologic protection in a murine model of peanut allergy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.1.43

Bacterial carriers and virus-like-particles as antigen delivery devices: role of dendritic cells in antigen presentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.1.43

Cross-presentation of virus-like particles by skin-derived CD8(-) dendritic cells: a dispensable role for TAP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.1.43

Uptake and presentation of hepatitis C virus-like particles by human dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.1.43

Recombinant parvovirus-like particles as an antigen carrier: a novel nonreplicative exogenous antigen to elicit protective antiviral cytotoxic T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.1.43

In vivo, dendritic cells can cross-present virus-like particles using an endosome-to-cytosol pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.1.43

MHC-I-restricted presentation of HIV-1 virion antigens without viral replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.1.43

Cross-presentation of phage particle antigen in MHC class II and endoplasmic reticulum marker-positive compartments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.1.43

Polylactide-co-glycolide microparticles with surface adsorbed antigens as vaccine delivery systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.1.43

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.1.43

Virus-like particles: flexible platforms for vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.1.43

A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.1.43

Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.1.43

A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.1.43

Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.1.43

Protection against osteoporosis by active immunization with TRANCE/RANKL displayed on virus-like particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.1.43

A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.1.43

Therapeutic vaccination to block receptor-ligand interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.1.43

Overcoming antigen masking of anti-amyloidbeta antibodies reveals breaking of B cell tolerance by virus-like particles in amyloidbeta immunized amyloid precursor protein transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.1.43

Therapeutic potential of Toll-like receptor 9 activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.1.43

CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.1.43

Nasal immunization with anthrax protective antigen protein adjuvanted with polyriboinosinic-polyribocytidylic acid induced strong mucosal and systemic immunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.1.43

Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.1.43

Imiquimod and resiquimod as novel immunomodulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.1.43

Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.1.43

Immunological responses after immunisation of mice with microparticles containing antigen and single stranded RNA (polyuridylic acid).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.1.43

Induction of autoantibodies to mouse CCR5 with recombinant papillomavirus particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.1.43

Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.1.43

A single vaccination with polyomavirus VP1/VP2Her2 virus-like particles prevents outgrowth of HER-2/neu-expressing tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.1.43

Effect of preexisting neutralizing antibodies on the anti-tumor immune response induced by chimeric human papillomavirus virus-like particle vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.1.43

21 January 2018

Identifiers

DOI

10.1586/14760584.7.1.43

1 reference

4 August 2017

1 reference